Chen Han, Wang Lin, Zhang Jisheng, Yan Xudong, Yu Longgang, Jiang Yan
The Affiliated Hospital of Qingdao University, Department of Otolaryngology Head and Neck Surgery, Qingdao, China.
The Affiliated Hospital of Qingdao University, Department of Otolaryngology Head and Neck Surgery, Qingdao, China.
Braz J Otorhinolaryngol. 2025 Apr 25;91(4):101633. doi: 10.1016/j.bjorl.2025.101633.
Direct comparison of the long-term effectiveness and safety of biologics for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is lacking. The study aimed to compare the long-term efficacy and safety of various biologics in the management of CRSwNP.
The PubMed, Embase, Cochrane Library, and Web of Science databases were searched from database inception to March 2024, to identify all relevant literature on the use of biologics for CRSwNP. The research protocol was registered on PROSPERO.Two independent reviewers screened the studies, extracted the data, and performed a quality assessment using the Cochrane Risk of Bias tool. Network meta-analysis was conducted using STATA 17.0 and Review Manager (Version 5.3).
Six studies with a minimum follow-up period of 52-weeks were analyzed, demonstrating the superior long-term efficacy of dupilumab compared to the other three biologics. The surface under the cumulative ranking curve were 100% for Nasal Polyp Score (NPS), 72.7% for Sino-Nasal Outcome Test-22 (SNOT-22), 94.6% for Visual Analogue Scale (VAS), and 100% for Nasal Congestion Score (NCS). In the comparison of NPS, dupilumab showed improvements of 1.84 (95% Confidence Interval [95% CI 0.78, 2.91]) over mepolizumab and 2.31 (95% CI 0.99, 3.63) over benralizumab. Among the symptom scores evaluated, only dupilumab achieved a significant improvement in NCS compared to benralizumab, with an improvement of 0.74 (95% CI 0.86, 1.19). No significant differences in adverse events was observed between biologics treatment or versus placebo.
Treatment with dupilumab in patients with CRSwNP has shown superior long-term efficacy in reducing NPS and various symptom scores compared to other biologics. However, the results should be interpreted with caution due to the heterogeneity of patient characteristics across the included studies (e.g., disease severity, history of surgery, use of oral corticosteroids).
缺乏对慢性鼻-鼻窦炎伴鼻息肉(CRSwNP)生物制剂长期有效性和安全性的直接比较。本研究旨在比较各种生物制剂在CRSwNP治疗中的长期疗效和安全性。
检索PubMed、Embase、Cochrane图书馆和Web of Science数据库,从建库至2024年3月,以识别所有关于生物制剂用于CRSwNP的相关文献。研究方案已在PROSPERO上注册。两名独立的评审员筛选研究、提取数据,并使用Cochrane偏倚风险工具进行质量评估。使用STATA 17.0和Review Manager(版本5.3)进行网络荟萃分析。
分析了6项随访期至少为52周的研究,结果表明度普利尤单抗与其他三种生物制剂相比具有更优的长期疗效。鼻息肉评分(NPS)的累积排名曲线下面积为100%,鼻窦-鼻腔结局测试-22(SNOT-22)为72.7%,视觉模拟量表(VAS)为94.6%,鼻充血评分(NCS)为100%。在NPS比较中,度普利尤单抗与美泊利单抗相比改善了1.84(95%置信区间[95%CI 0.78, 2.91]),与贝那利珠单抗相比改善了2.31(95%CI 0.99, 3.63)。在评估的症状评分中,与贝那利珠单抗相比,只有度普利尤单抗在NCS方面有显著改善,改善值为0.74(95%CI 0.86, 1.19)。生物制剂治疗组与安慰剂组之间在不良事件方面未观察到显著差异。
与其他生物制剂相比,度普利尤单抗治疗CRSwNP患者在降低NPS和各种症状评分方面显示出更优的长期疗效。然而,由于纳入研究中患者特征的异质性(如疾病严重程度、手术史、口服糖皮质激素的使用情况),对结果的解释应谨慎。